1. Antioxidant Role of PRGF on RPE Cells after Blue Light Insult as a Therapy for Neurodegenerative Diseases.
- Author
-
Suárez-Barrio C, Del Olmo-Aguado S, García-Pérez E, de la Fuente M, Muruzabal F, Anitua E, Baamonde-Arbaiza B, Fernández-Vega-Cueto L, Fernández-Vega L, and Merayo-Lloves J
- Subjects
- Adult, Animals, Cell Line, Cell Survival physiology, Epithelial Cells metabolism, Female, Humans, Light, Mitochondria metabolism, Oxidation-Reduction, Oxidative Stress physiology, Rats, Rats, Wistar, Reactive Oxygen Species metabolism, Retinal Pigment Epithelium metabolism, Signal Transduction physiology, Antioxidants metabolism, Intercellular Signaling Peptides and Proteins metabolism, Neurodegenerative Diseases metabolism, Plasma metabolism, Retina metabolism
- Abstract
Oxidative stress has a strong impact on the development of retinal diseases such as age-related macular degeneration (AMD). Plasma rich in growth factors (PRGF) is a novel therapeutic approach in ophthalmological pathologies. The aim of this study was to analyze the antioxidant effect of PRGF in retinal epithelial cells (EPR) in in vitro and ex vivo retinal phototoxicity models. In vitro analyses were performed on ARPE19 human cell line. Viability and mitochondrial status were assessed in order to test the primary effects of PRGF. GSH level, and protein and gene expression of the main antioxidant pathway (Keap1, Nrf2, GCL, HO-1, and NQO1) were also studied. Ex vivo analyses were performed on rat RPE, and HO-1 and Nrf2 gene and protein expression were evaluated. The results show that PRGF reduces light insult by stimulating the cell response against oxidative damage and modulates the antioxidant pathway. We conclude that PRGF's protective effect could prove useful as a new therapy for treating neurodegenerative disorders such as AMD., Competing Interests: C.S.B., S.O.A., E.G.P., B.B.A., L.F.V.C., L.F.V., and J.M.LL. declare no conflict of interest. M.F., F.M. and E.A. declare the following competing financial interest(s): E.A. is the Scientific Director and M.F. and F.M. are researchers at BTI Biotechnology Institute, a company that investigates in the fields of oral implantology and PRGF-Endoret technology.
- Published
- 2020
- Full Text
- View/download PDF